Ipamorelin

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) functioning as a selective growth hormone secretagogue that binds to ghrelin receptors (GHS-R1a) in the anterior pituitary to stimulate growth hormone release. Originally developed by Novo Nordisk, it represents the first GHRP-receptor agonist with selectivity for GH release comparable to GHRH, notably without stimulating cortisol or ACTH secretion even at doses 200-fold above therapeutic levels. While investigated in Phase II clinical trials for postoperative ileus (discontinued due to lack of efficacy), ipamorelin demonstrates promising preclinical effects on bone growth, muscle preservation, and metabolic function. Currently, it lacks FDA approval for any indication and exists in a regulatory gray area where it's marketed as a research chemical but widely used off-label in peptide therapy clinics for anti-aging, body composition optimization, and recovery enhancement, while simultaneously being prohibited by WADA as a performance-enhancing substance in competitive sports.

Growth Hormone Stimulation

• Selective GH release: Ipamorelin demonstrates high selectivity for growth hormone secretion without elevating ACTH, cortisol, prolactin, FSH, LH, or TSH levels, providing a cleaner hormonal profile than other growth hormone secretagogues ^[1][2]
• Dose-proportional pharmacokinetics: Human studies show predictable dose-response relationships with peak GH stimulation occurring at 0.67 hours post-administration and a terminal half-life of approximately 2 hours ^[3]
• Pulsatile GH release: Mimics natural physiological patterns of growth hormone secretion, potentially reducing risks associated with continuous elevation ^[2][7]

Bone Health and Density

• Longitudinal bone growth: Animal studies demonstrate dose-dependent increases in bone growth rates from 42 μm/day to 52 μm/day at higher doses (p<0.0001), suggesting potential applications in growth disorders ^[4]
• Glucocorticoid-induced bone loss prevention: Research shows ipamorelin increases periosteal bone formation rate four-fold when combined with glucocorticoids, potentially negating steroid-induced bone deterioration ^[5]
• Bone mineral density improvements: Preclinical studies in female rats showed significant increases in bone mineral content after 12 weeks of treatment measured via DEXA scanning ^[4][5]

Body Composition and Metabolic Effects

• Lean mass preservation: Ipamorelin promotes muscle retention during caloric deficits and may support modest lean mass gains through elevated IGF-1 production, though effects are not anabolic like traditional steroids ^[6][7]
• Enhanced lipolysis: The peptide accelerates fat breakdown while maintaining muscle tissue, forcing metabolic preference toward stored fat utilization for energy ^[7]
• Weight management: Animal studies in GH-deficient mice showed 15.3% body weight increases over 9 weeks, with pronounced dose-dependent effects on body weight gain ^[4][6]

Recovery and Tissue Repair

• Accelerated wound healing: Growth hormone elevation promotes tissue repair through increased collagen production, reduced inflammation, and enhanced connective tissue regeneration ^[7][8]
• Improved sleep architecture: Enhancement of slow-wave deep sleep stages where most muscle and connective tissue repair occurs, supporting natural circadian GH rhythms ^[7][8]
• Muscle recovery: GH/IGF-1 elevation enhances protein synthesis, satellite cell activation, and recovery from training-induced damage, reducing post-exercise recovery time ^[7][8]
• Joint and connective tissue support: Supports recovery of tendons, ligaments, and joints through GH and IGF-1 mediated connective tissue health improvements ^[7][8]

Gastrointestinal Effects

• Gastric motility: Preclinical research demonstrates ipamorelin reduces gastric retention from 78% to 52% in postoperative ileus models, normalizing contractile responses to acetylcholine and electrical field stimulation ^[9]
• Intestinal transit restoration: Higher doses restore small intestinal transit parameters to near-normal levels following abdominal surgery ^[9]

Insulin Regulation

• Pancreatic insulin secretion: Ipamorelin evokes significant insulin release from pancreatic tissue in both normal and diabetic rats through calcium channel and adrenergic receptor pathways ^[10]

Clinical Safety Profile

• Hormonal selectivity advantage: Unlike GHRP-2 and GHRP-6, ipamorelin does not stimulate ACTH or cortisol secretion even at doses exceeding 200-fold the ED50 for GH release, reducing endocrine disruption risks ^[1][2]
• Well-tolerated in trials: A Phase II randomized controlled trial in 114 bowel resection patients showed comparable adverse event rates between ipamorelin (87.5%) and placebo (94.8%) groups, with the drug considered well-tolerated ^[11]
• Limited long-term safety data: Most studies cited are short-duration with small sample sizes, providing insufficient evidence for long-term safety assessment in humans ^[12]
• Common mild side effects: Injection site reactions (redness, soreness, swelling), headaches, dizziness, nausea (particularly during initiation), mild fluid retention or edema, and transient increased appetite due to ghrelin mimetic properties ^[7][12]

Metabolic and Endocrine Concerns

• Glucose metabolism effects: Growth hormone secretagogues may increase fasting blood glucose and HbA1c levels; patients with diabetes should monitor blood sugar levels closely as ipamorelin may influence glucose metabolism and insulin resistance ^[12]
• Contraindicated in uncontrolled diabetes: Severe diabetes mellitus without medical supervision is a contraindication due to potential impacts on insulin sensitivity ^[7]
• Insulin sensitivity: GH protocols can negatively impact insulin resistance when used inappropriately or at excessive doses ^[7]

Cancer and Proliferative Risks

• Theoretical cancer concerns: Association between ipamorelin and cancer risk exists due to GH and IGF-1's proliferative properties; long-term effects on cancer development remain unknown and require further study ^[2][7]
• Active malignancy contraindication: Should be avoided in patients with active malignancy, recent cancer, or history of hormone-sensitive cancers due to growth-promoting mechanisms ^[7]

Cardiovascular Safety

• Severe cardiovascular disease contraindication: Not recommended for patients with severe heart disease; one hip fracture recovery trial with the related compound ibutamoren was stopped early due to congestive heart failure concerns (4 cases vs 1 placebo) ^[12]
• Fluid retention: Potential for fluid retention may exacerbate cardiovascular conditions in susceptible individuals ^[7][12]

Regulatory Status and Gray Market Concerns

• No FDA approval: Ipamorelin is not FDA-approved for any therapeutic indication and remains investigational; categorized as a 503A/503B compounded drug ^[7]
• Discontinued clinical development: Phase II trials for postoperative ileus were discontinued due to lack of efficacy, halting further pharmaceutical development ^[11]
• WADA prohibited substance: Listed as class S2.2 on the World Anti-Doping Agency prohibited list, banned at all times in competitive sports ^[13]
• Research chemical gray market: Available through unregulated channels as "research chemicals" not held to human-use safety standards; concerns include contamination with microbes, heavy metals, solvent residues, unknown chemicals, and dosing inaccuracies ^[7]

Special Population Contraindications

• Pregnancy and lactation: Absolutely contraindicated in pregnant or breastfeeding women due to insufficient safety data and unknown effects on fetal/infant development ^[7]
• Endocrine disorders: Should be avoided in patients with untreated endocrine disorders that may be exacerbated by growth hormone axis stimulation ^[7]

Administration Risks

• Injection-related complications: As with all injectable peptides, risks include improper sterile technique leading to infections, allergic/hypersensitivity reactions (rare), and local tissue damage from repeated injections ^[7][12]
• Medical supervision required: Use should only occur under qualified medical supervision with appropriate monitoring for adverse effects and efficacy ^[7][12]